John C Flickinger Jr
Overview
Explore the profile of John C Flickinger Jr including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
270
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Flickinger Jr J, Staudt R, Singh J, Carlson R, Barton J, Baybutt T, et al.
NPJ Vaccines
. 2022 Jun;
7(1):61.
PMID: 35739202
Strategies to augment immunity to self/neoantigens expressed by cancers are urgently needed to expand the proportion of patients benefiting from immunotherapy, particularly for GI cancers where only a fraction of...
2.
Flickinger Jr J, Singh J, Yarman Y, Carlson R, Barton J, Waldman S, et al.
Front Immunol
. 2022 Mar;
13:855759.
PMID: 35355987
The Gram-positive bacterium (Lm) is an emerging platform for cancer immunotherapy. To date, over 30 clinical trials have been initiated testing Lm cancer vaccines across a wide variety of cancers,...
3.
Lisby A, Flickinger Jr J, Bashir B, Weindorfer M, Shelukar S, Crutcher M, et al.
Expert Rev Precis Med Drug Dev
. 2021 May;
6(2):117-129.
PMID: 34027103
Introduction: Colorectal cancer (CRC) is one of the most-deadly malignancies worldwide. Current therapeutic regimens for CRC patients are relatively generic, based primarily on disease type and stage, with little variation....
4.
Flickinger Jr J, Rappaport J, Barton J, Baybutt T, Pattison A, Snook A, et al.
Biomark Med
. 2021 Jan;
15(3):201-217.
PMID: 33470843
Gastrointestinal cancers encompass a diverse class of tumors arising in the GI tract, including esophagus, stomach, pancreas and colorectum. Collectively, gastrointestinal cancers compose a high fraction of all cancer deaths,...
5.
Flickinger Jr J, Singh J, Carlson R, Leong E, Baybutt T, Barton J, et al.
J Immunother Cancer
. 2020 Aug;
8(2).
PMID: 32819976
Background: Adenovirus serotype 5 (Ad5) is a commonly used viral vector for transient delivery of transgenes, primarily for vaccination against pathogen and tumor antigens. However, endemic infections with Ad5 produce...
6.
Carlson R, Flickinger Jr J, Snook A
Toxins (Basel)
. 2020 Apr;
12(4).
PMID: 32283684
The ability of the immune system to precisely target and eliminate aberrant or infected cells has long been studied in the field of infectious diseases. Attempts to define and exploit...
7.
Stem J, Flickinger Jr J, Merlino D, Caparosa E, Snook A, Waldman S
Regen Med
. 2019 Apr;
14(4):331-343.
PMID: 31025613
Gastrointestinal cancers remain a tremendous burden on society. Despite advances in therapy options, including chemotherapy and radiation, cancer mortality from recurrences and metastases occur frequently. Cancer stem cells (CSCs) drive...
8.
Snook A, Baybutt T, Xiang B, Abraham T, Flickinger Jr J, Hyslop T, et al.
J Immunother Cancer
. 2019 Apr;
7(1):104.
PMID: 31010434
Background: The colorectal cancer antigen GUCY2C exhibits unique split tolerance, evoking antigen-specific CD8, but not CD4, T-cell responses that deliver anti-tumor immunity without autoimmunity in mice. Here, the cancer vaccine...
9.
Abraham T, Flickinger Jr J, Waldman S, Snook A
J Immunol
. 2019 Jan;
202(4):1301-1310.
PMID: 30642983
Characterizing self-tolerance mechanisms and their failure is critical to understand immune homeostasis, cancer immunity, and autoimmunity. However, examination of self-tolerance mechanisms has relied primarily on transgenic mice expressing TCRs targeting...
10.
Baybutt T, Flickinger Jr J, Caparosa E, Snook A
Clin Pharmacol Ther
. 2018 Nov;
105(1):71-78.
PMID: 30406956
In 2017, the US Food and Drug Administration approved the first two novel cellular immunotherapies using synthetic, engineered receptors known as chimeric antigen receptors (CARs), tisagenlecleucel (Kymriah) and axicabtagene ciloleucel...